FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2944288209> ?p ?o ?g. }

• W2944288209 endingPage "10" @default.
• W2944288209 startingPage "S" @default.
• W2944288209 abstract "Overview of exocrine pancreatic insufficiency (EPI) and related issuesThe pancreas, an essential part of the gastrointestinal (GI) system, is functionally composed of exocrine and endocrine constituents. Because there is minimal anatomic separation of the exocrine and endocrine pancreatic function, disease states that cause disruption or damage in one component of the organ may lead to defects in the other component.8EPI is a relatively uncommon but severe condition that is associated with a variety of complex disorders such as cystic fibrosis (CF), pancreatic cancer, gastric/pancreatic surgery, short bowel syndrome, and chronic pancreatitis. Physiological and biochemical effects of EPI include decreased production and secretion of lipase, increased lipase destruction and degradation, and GI motility disorders. The deficiency in pancreatic enzymes (lipase, amylase, protease) results in impaired digestion and subsequent absorption of all nutrients, fats and fat-soluble vitamins being the most clinically relevant.8Steatorrhea, diarrhea, weight loss, abdominal discomfort, and bloating are hallmarks of EPI. In addition to lifestyle modification (eg, alcohol abstinence, frequent low-volume meals), the typical treatment for EPI is pancreatic enzyme replacement therapy (PERT), the clinical efficacy of which is inconsistent.9 Left untreated, or inadequately controlled, the condition leads to increasingly severe GI symptoms, reduced caloric intake, and inability to gain and/or maintain weight, placing the patient at risk for malnutrition.Malabsorption of fats dramatically increases the risk for malnutrition in patients with EPI.10 Because malnutrition further compromises treatment for the medical conditions underlying EPI, enteral nutrition (EN) becomes a vital therapeutic intervention for stabilizing body mass index (BMI) in some cases.3 EN formulas contain fats as well as carbohydrates, proteins, vitamins, and minerals to help prevent or address nutritional deficiencies related to malabsorption.Nutrition support therapy is more complex than commonly appreciated, particularly when prescribed for patients with EPI. Severely pancreatic insufficient patients are unable to digest and absorb long-chain triglycerides contained in EN formulas – particularly healthy fats such as docosahexanoic acid (DHA) and eicosapentaenoic acid (EPA). Currently, there is no published evidence to support the use of any Food and Drug Administration (FDA)-approved PERT products in enteral feedings, and existing clinical guidelines do not support administration of enzymes by mixing them into EN formulas.3 Factors such as care settings and nutritional formula types must be considered on a case-by-case basis, and complications must be anticipated and avoided; for example, the use of crushed PERT capsule contents in enteral feedings, or capsule contents administered directly though the feeding tube, causes tube clogging and requires frequent monitoring.11From the patient perspective, some with CF rely on nocturnal EN for adequate caloric intake to maintain and hopefully improve BMI and lung function. Following pancreatic and other GI surgeries, EN is essential for patients who experience gastroparesis and are unable to tolerate oral meals. Lacking an appetite for food, patients with pancreatic cancer often use EN to prevent cachexia. EN is helpful for some patients with cerebral palsy who experience pain while eating solid food." @default.
• W2944288209 created "2019-05-16" @default.
• W2944288209 creator A5026919427 @default.
• W2944288209 creator A5033456451 @default.
• W2944288209 creator A5050513604 @default.
• W2944288209 creator A5061005032 @default.
• W2944288209 creator A5084650153 @default.
• W2944288209 date "2019-06-01" @default.
• W2944288209 modified "2023-10-18" @default.
• W2944288209 title "Optimizing Clinical and Cost Outcomes for Patients on Enteral Nutrition Support for Treatment of Exocrine Pancreatic Insufficiency: <i>Proceedings from an Expert Advisory Board Meeting</i>" @default.
• W2944288209 cites W2049071728 @default.
• W2944288209 cites W2077862337 @default.
• W2944288209 cites W2101880068 @default.
• W2944288209 cites W2111069513 @default.
• W2944288209 cites W2301930833 @default.
• W2944288209 cites W2332899068 @default.
• W2944288209 cites W2547555937 @default.
• W2944288209 cites W2560155202 @default.
• W2944288209 cites W2610981734 @default.
• W2944288209 cites W2736033683 @default.
• W2944288209 cites W2736180875 @default.
• W2944288209 cites W2754323582 @default.
• W2944288209 cites W2791385328 @default.
• W2944288209 cites W2803041799 @default.
• W2944288209 cites W2887525724 @default.
• W2944288209 cites W2889765177 @default.
• W2944288209 doi "https://doi.org/10.1089/pop.2019.0042" @default.
• W2944288209 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6537119" @default.
• W2944288209 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31066618" @default.
• W2944288209 hasPublicationYear "2019" @default.
• W2944288209 type Work @default.
• W2944288209 sameAs 2944288209 @default.
• W2944288209 citedByCount "3" @default.
• W2944288209 countsByYear W29442882092020 @default.
• W2944288209 countsByYear W29442882092021 @default.
• W2944288209 countsByYear W29442882092022 @default.
• W2944288209 crossrefType "journal-article" @default.
• W2944288209 hasAuthorship W2944288209A5026919427 @default.
• W2944288209 hasAuthorship W2944288209A5033456451 @default.
• W2944288209 hasAuthorship W2944288209A5050513604 @default.
• W2944288209 hasAuthorship W2944288209A5061005032 @default.
• W2944288209 hasAuthorship W2944288209A5084650153 @default.
• W2944288209 hasBestOaLocation W29442882091 @default.
• W2944288209 hasConcept C126322002 @default.
• W2944288209 hasConcept C177713679 @default.
• W2944288209 hasConcept C2777152358 @default.
• W2944288209 hasConcept C2778764654 @default.
• W2944288209 hasConcept C44315111 @default.
• W2944288209 hasConcept C71924100 @default.
• W2944288209 hasConcept C78722104 @default.
• W2944288209 hasConceptScore W2944288209C126322002 @default.
• W2944288209 hasConceptScore W2944288209C177713679 @default.
• W2944288209 hasConceptScore W2944288209C2777152358 @default.
• W2944288209 hasConceptScore W2944288209C2778764654 @default.
• W2944288209 hasConceptScore W2944288209C44315111 @default.
• W2944288209 hasConceptScore W2944288209C71924100 @default.
• W2944288209 hasConceptScore W2944288209C78722104 @default.
• W2944288209 hasIssue "S1" @default.
• W2944288209 hasLocation W29442882091 @default.
• W2944288209 hasLocation W29442882092 @default.
• W2944288209 hasLocation W29442882093 @default.
• W2944288209 hasLocation W29442882094 @default.
• W2944288209 hasLocation W29442882095 @default.
• W2944288209 hasOpenAccess W2944288209 @default.
• W2944288209 hasPrimaryLocation W29442882091 @default.
• W2944288209 hasRelatedWork W158612116 @default.
• W2944288209 hasRelatedWork W1986249681 @default.
• W2944288209 hasRelatedWork W2000090759 @default.
• W2944288209 hasRelatedWork W2055118237 @default.
• W2944288209 hasRelatedWork W2060205069 @default.
• W2944288209 hasRelatedWork W2135251493 @default.
• W2944288209 hasRelatedWork W2259416242 @default.
• W2944288209 hasRelatedWork W2316756949 @default.
• W2944288209 hasRelatedWork W2415779764 @default.
• W2944288209 hasRelatedWork W2527025911 @default.
• W2944288209 hasVolume "22" @default.
• W2944288209 isParatext "false" @default.
• W2944288209 isRetracted "false" @default.
• W2944288209 magId "2944288209" @default.
• W2944288209 workType "article" @default.